Pyxis Oncology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Operating expenses | — | — | $82.2M | $123.5M | $69.7M |
| Cost of revenue | $2.4M | $475,000 | — | — | — |
| Cash from operations | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Capital expenditure | $9,000 | $237,000 | $6.7M | $6.4M | $540,000 |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Impairments | $0 | $21.0M | $0 | — | — |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
Shares outstanding 63.4M · Free float 78.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.